Barclays Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $156

Benzinga Newsdesk www.benzinga.com Negative 90.4%

Neg 90.4% Neu 0% Pos 0%

Barclays analyst Eliana Merle maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and lowers the price target from $157 to $156.